Credibility built into the structure, not the sales pitch.
Biotech site design carries credibility through how the pipeline, team and data are structurally presented, doing the work a customer testimonial or case study would do for a company with a marketed product.
Without a marketed product, the site’s structure — how the pipeline, team and data are organised — has to do the credibility work a customer testimonial or case study would normally do for a commercial company.
A biotech site is frequently the only public evidence an investor has before a meeting, which raises the cost of any vague or unverifiable claim on it. Getting the design right starts from that fact, not from a moodboard.
An architecture that carries credibility through structure rather than testimonials, a component system built around pipeline and team presentation, and a review of where the current site currently under-proves what it claims.
Without a marketed product, credibility has to come from how the pipeline, team and data are presented structurally — the architecture carries weight that a more established company would put on customer testimonials or case studies.
For an investor, a partner or a senior candidate, the pipeline is the company. It is the first thing opened and usually the only thing studied properly, and in most biotech sites it is a single image — uneditable, unreadable on a phone, invisible to search, and impossible to link to at programme level. Building it as structured content instead gives every asset its own addressable page with mechanism, indication, stage, modality and supporting publications, lets the overview render from the same data so the two can never disagree, and means an update after a milestone takes minutes rather than a request to a designer.
A biotech website is usually built at one moment — a launch, a financing, a rebrand — and then has to absorb several years of change without another project budget: new programmes, publications, milestone announcements, a growing team, and eventually clinical-stage material with a different regulatory character. Sites built as a fixed set of designed pages cannot absorb that, and the familiar result is a site that visibly stopped being updated eighteen months ago, which is a poor signal to send to an investor. The alternative is fewer bespoke layouts and more repeatable content types your own team can extend.
What comes up when scoping a site for this category.
An investor or prospective scientific partner conducting quick diligence before a meeting, looking for pipeline stage, leadership background, and publication history rather than browsing generally. That reader is more specific than the generic pharmaceutical visitor most templates assume, and expects to verify claims against public sources quickly rather than accept a polished summary at face value.
Credibility before launch rests on specificity rather than promotional language: clear pipeline stage, named leadership with linkable track records, and publication or trial registry references an investor can check independently. A site that substitutes broad claims about innovation for those concrete, checkable details reads as less credible to the exact audience it is trying to reach, since that audience knows what verification looks like.
Yes. Alongside the website, we build the pipeline visualisations, investor relations content, and publication archives that support ongoing diligence between funding rounds. For a biotech, keeping pipeline stage and trial status current as programmes advance matters continuously, since stale status information is one of the fastest ways to undermine the credibility the site is meant to build. See Biotech for the full range.
Often, at least partially, since the credibility job the site performs changes once there is a commercial product to sell rather than only a pipeline to defend. The architecture usually needs to shift toward prescriber and patient-facing content alongside the investor material, and treating that as an extension rather than a full rebuild avoids discarding content still doing useful work.
Build the parts that diligence will look at now, and leave the rest. Investors and their advisers research the science and the team well before a first meeting, so the pipeline, the publications and the team pages earn their value during the raise itself. What can safely wait is the broader brand and campaign work, which is easier to do well once the round has clarified the story. Building in that order also means the site grows rather than being replaced.
A design that photographs well and still loses an investor or scientific partner doing quick diligence halfway through the page. Tell us what you have tried and we will tell you what we think is actually going on. Tell us your situation and we will tell you what a rebuild for an investor or scientific partner doing quick diligence would actually change.